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Abstract
Recently, fatty acid transport across the plasma membrane has been shown to be a key process that contributes to the regulation
of fatty acid metabolism in the heart. Since AMP kinase activation by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside
(AICAR) stimulates fatty acid oxidation, as well as the expression of selected proteins involved with energy provision, we
examined (a) whether AICAR induced the expression of the fatty acid transporters FABPpm and FAT/CD36 in cardiac myocytes
and in perfused hearts and (b) the signaling pathway involved. Incubation of cardiac myocytes with AICAR increased the
protein expression of the fatty acid transporter FABPpm after 90 min (+27%, P < 0.05) and this protein remained stably
overexpressed until 180 min. Similarly, FAT/CD36 protein expression was increased after 60 min (+38%, P < 0.05) and
remained overexpressed thereafter. Protein overexpression, which occurred via transcriptional mechanisms, was dependent
on the AICAR concentration, with optimal induction occurring at AICAR concentrations 1–5 mM for FABPpm and at 2–
8 mM for FAT/CD36. The AICAR (2 h, 2 mM AICAR) effects on FABPpm and FAT/CD36 protein expression were similar in
perfused hearts and in cardiac myocytes. AICAR also induced the plasmalemmal content of FAT/CD36 (+49%) and FABPpm
(+42%) (P < 0.05). This was accompanied by a marked increase in the rate of palmitate transport (2.5 fold) into giant
sarcolemmal vesicles, as well as by increased rates of palmitate oxidation in cardiac myocytes. When the AICAR-induced AMPK
phosphorylation was blocked, neither FAT/CD36 nor FABPpm were overexpressed, nor were palmitate uptake and oxidation
increased. This study has revealed that AMPK activation stimulates the protein expression of both fatty acid transporters,
FAT/CD36 and FABPpm in (a) time- and (b) dose-dependent manner via (c) the AMPK signaling pathway. AICAR also (d)
increased the plasmalemmal content of FAT/CD36 and FABPm, thereby (e) increasing the rates of fatty acid transport. Thus,
activation of AMPK is a key mechanism regulating the expression as well as the plasmalemmal localization of fatty acid
transporters. (Mol Cell Biochem 288: 201–212, 2006)
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Long chain fatty acids (LCFAs) are the principal myocardial
energy substrate [1]. AMP kinase (AMPK) has been impli-
cated to play an important regulatory role in cardiac myocyte
fatty acid oxidation [2, 3]. Active forms of AMP kinase cause
phosphorylation of ACC (acetyl-CoA carboxylase), result-
ing in its inactivation with a concomitant decrease in the
intracellular levels of malonyl-CoA [4, 5]. In cardiac my-
ocytes [6], and in muscle [7–9], the reduction of malonyl-CoA
reduces the inhibition on carnitine palmitoyl-transferase-1
(CPT-1), thereby promoting the increase in mitochondrial
fatty acid uptake and oxidation. Recently, it was also pro-
posed that AMPK activation may stimulate cardiac LCFA
oxidation by increasing the rate of LCFA uptake across
the plasma membrane in the isolated working heart [10]
or in vivo [11]. However, definitive mechanisms were not
examined.
The synthesis or storage of LCFAs is a limited process in
heart [12], and therefore, this tissue is highly dependent on the
blood borne delivery of LCFAs. It is now well-documented
that LCFA uptake in many tissues [13–16], including the heart
[17, 18], is facilitated by fatty acid transporters. Several fatty
acid transporters are expressed in heart, including fatty acids
translocase (FAT/CD36), plasma membrane associated fatty
acid binding protein (FABPpm) and fatty acid transporter 1
(FATP-1) [18–22], although it has recently been shown that
FATP-6 is present in far greater quantities in the heart than
FATP-1 [23]. The molecular mechanisms by which these pro-
teins move LCFAs across the plasma membrane are not yet
clear. These proteins may function in trapping LCFAs, and
transmembrane translocation occurs by flip-flop [24]. Despite
not knowing precisely how protein-mediated LCFA traffick-
ing occurs across the plasma membrane, there is strong ex-
perimental evidence for the involvement of FAT/CD36 and
FABPpm in this process. Work in our laboratory has shown
that the expression of FABPpm and FAT/CD36 and their sub-
cellular distribution, as well as LCFA transport, are regulated
acutely and chronically by selected physiologic stimuli [13,
17, 18, 20, 22, 25].
Acute stimulation of LCFA transport can occur within min-
utes in heart and skeletal muscle, and is stimulated by insulin
[17, 22] as well as by contraction [13, 18]. This increase
in LCFA uptake is attributable to insulin-, and contraction-
induced translocation of FAT/CD36 to the plasma mem-
brane [13, 17, 18, 22]. However, insulin stimulation (30 min)
failed to stimulate the translocation of FABPpm from an
intracellular depot to the plasma membrane [26], whereas
the 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside
(AICAR)-stimulated activation of AMPK (30 min) induced
the translocation of both FABPpm and FAT/CD36 [26], from
an intracellular depot to the plasma membrane. Thus, under
acute stimulation (≤30 min), and in the absence of their
altered expression, FABPpm and FAT/CD36 exhibit differ-
ential responsiveness to selected metabolic stimuli.
Chronic regulation (hours–days) of LCFA transport and
transporters has also been shown. Within 2 h, insulin upregu-
lates the protein expression of FAT/CD36, but not FABPpm,
in cardiac myocytes [20]. This insulin-induced overexpres-
sion of FAT/CD36 and its concomitant translocation to the
plasma membrane were positively correlated with the in-
creased rates of fatty acid transport into the heart [20]. In-
creased muscle activity (chronic muscle stimulation for 7
days) also upregulated the protein expression and plasmalem-
mal content of both FAT/CD36 and FABPpm, and increased
the rate of LCFA transport [27, 28]. In contrast, denervation
of muscle (7 days), which eliminates muscle activity and in-
duces marked changes in the expression of many genes [29],
failed to alter FABPpm and FAT/CD36 protein expression.
However, the plasmalemmal content of these proteins was
reduced, as was the rate of LCFA transport [28]. Thus, it ap-
pears that prolonged stimulation with insulin and prolonged
changes in muscle activity can alter the expression and/or sub-
cellular distribution of FABPpm and FAT/CD36 in heart or
skeletal muscle, with concurrent changes in LCFA transport.
Contractile activity is known to activate of AMP kinase
(AMPK), and it is thought that phosphorylation of this ki-
nase is central to the contraction-induced upregulation of
fatty acid oxidation as well as the expression of selected
metabolic genes (cf [30]). For example, (a) aminoimidazole-
4-carboxamide-1-β-D-ribofuranoside (AICAR)-stimulated
AMPK activation acutely (30–60 min) increases LCFA oxi-
dation in the absence of any changes in protein expression
[31, 32], and (b) prolonged (hours - weeks) AMPK activation
by AICAR is a key stimulus for increasing the expression of
metabolic proteins in skeletal muscle, including UCP3, PGC-
1α, MCT4, GLUT4, citrate synthase, 3-hydroxyacyl-CoA
dehydrogenase [33–35]. However, it is not known whether
prolonged AMPK activation induces the expression of se-
lected metabolic genes in the heart as has been observed in
skeletal muscle. There is some evidence that AMPK acti-
vation has tissue-specific effects [36]. In recent years it has
been suggested cardiac fatty acid metabolism in vivo is in-
fluenced by the uptake of LCFAs [3, 10, 11], a process that
is mediated by fatty acid transporters in the heart (cf. [37,
38]). In view of the key role of AMPK activation of gene
expression in muscle, we hypothesized that AMPK activa-
tion, when prolonged, also regulates the expression of the
fatty acid transporters FAT/CD36 and FABPpm in the heart,
which would be expected to increase the transport rate of
LCFAs and their subsequent oxidation. Specifically, we ex-
amined (a) the time- and dose-dependent effects of AICAR
on FABPpm and FAT/CD36 protein expression in cardiac
myocytes, (b) whether the effects of AICAR on FABPpm
and FAT/CD36 protein expression were similar in cardiac
myocytes and in the perfused heart, (c) whether the AICAR-
induced upregulation of FAT/CD36 and FABPm increased
their plasmalemmal content, thereby increasing myocardial
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LCFA transport, leading to an increase in LCFA oxidation,
and finally, (d) we also examined whether the inhibition of
AMPK activation, as well as other signaling pathways, pre-
vented the increased expression of FAT/CD36 and FABPpm,




The PI3 kinase inhibitor (LY 294002) and MEK1/2 kinase
inhibitor (UO126) were purchased from Cell Signaling
Technology (Beverly, MA). PKC ζ /λ inhibitor (myristoy-
lated PKC ζ /λ pseudosubstrate was purchased from Cal-
biochem (San Diego, CA) and ARA (adenine 9-β-D-arabino-
furanoside) was obtained from Sigma-Aldrich (St. Louis,
MO). Antibodies used in this study were as follows: MO25
was used to detect FAT/CD36 [39]] and FABPpm antisera was
used to detect FABPpm [40]. Total and phosphorylated quan-
tities of selected proteins were determined with commercially
available antibodies (Akt kinase: anti-Akt1/2/3 and anti-
phospho-Akt1/2/3 (Ser 473 or Thr 308), Santa Cruz Biotech-
nology, (Santa Cruz, CA); MAP kinase: anti-p42/44 ERK1/2,
anti-phospho-p42/44 ERK1/2 (Thr202/Thr 204) and anti-
pMEK1/2 (Ser 217/221) Cell Signaling Technology (Beverly,
MA); PKC ζ /λ kinase: anti- PKC ζ /λ and rabbit anti-
phospho-PKC ζ /λ (Thr410/403), Cell Signaling Technol-
ogy (Beverly, MA); AMP kinase: anti-phospho-AMPK (Thr
174), rabbit anti-AMPK, anti-phospho-ACC (Ser 79), Cell
Signaling Technology (Beverly, MA). Goat-anti-rabbit sec-
ondary antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). [1-14C]-palmitate was purchased
from Amersham Life Science (Little Chalfont, UK). BSA
(fraction V, essentially FA free (confirmed in separate anal-
yses)) and phloretin were obtained from Sigma-Aldrich
(St. Louis, MO). Collagenase type II was purchased from
Worthington (Lakewood, NJ, U.S.A.). The cell-permeate
adenosine analog, 5-aminoimidazole-4-carboxamide-1-b-D-
ribofuranoside (AICAR), was purchased from Toronto Re-
search Chemicals Inc., (North York, ON, Canada). All other
chemicals were obtained from Sigma-Aldrich (St. Louis,
MO).
Animals and cardiac myocytes isolation
Male Wistar rats (250–300 g) were bred on site and main-
tained at 20 ◦C on a reverse light-dark cycle in approved
animal holding facilities. The animals had unrestricted access
to food and water. This study was approved by the committee
on animal care at the University of Guelph.
Cardiac myocytes were isolated from male adult rats ac-
cording to the procedure previously described by us [18,
20, 22] based on procedures developed by Fischer et al.
[41]. Briefly, rats were anaesthetized using Somnotol (50–
60 mg/100 g, i.p.) combined with heparin (300 i.u./100 g,
i.p.). The hearts were quickly removed and placed in ice-
cold Krebs-Henseleit bicarbonate buffer, (KHB, pH 7.4),
and equilibrated with 95% O2 and 5% CO2. Subsequently,
hearts were perfused (20 min) in a recirculating mode, with
KHB buffer supplemented with 0.7% (w/v) BSA, 15 mM
butanedione monoxime and 0.075% (w/v) collagenase type
II. CaCl2 was added to a final concentration 0.2 mM dur-
ing the perfusion. After 20 min hearts were removed and
gently minced. The suspension was incubated for another
10 min at 37 ◦C, while the CaCl2 concentration was gradu-
ally raised to 1.0 mM. Then cells were filtered through 0.2 mm
nylon gauze and centrifuged for 2 min at 20 ×g. After iso-
lation, cells were washed twice and suspended in 20 ml of
medium A (KHB buffer supplemented with 2% (w/v) BSA
and 1 mM CaCl2). At the beginning of the experiments the
percentage of rod-shaped cells excluding trypan blue was
determined. For all the experiments ≥80% of the cardiac
myocytes were structurally intact. For determination of car-
diac myocytes wet mass, duplicate aliquots of the cells sus-
pensions were centrifuged (2–3 sec., at 10, 000 × g). The
yield of cardiac myocytes ranged from 500–600 mg per single
heart.
Effects of AICAR on FABPpm and FAT/CD36
To examine the effects of AICAR on cardiac myocytes
FABPpm and FAT/CD36 expression, we performed time-
and dose- dependent studies. After the isolation, cardiac my-
ocytes were incubated in medium A with or without addi-
tions of AICAR (2 mM, unless otherwise stated). All studies
were performed at 37 ◦C and cardiac myocytes viability was
> 80% for 3 h (data not shown). The time course studies
(2 mM AICAR, 0 min–180 min) and dose response studies
(0–8 mM AICAR, 120 min) were performed to examine the
effects of AICAR on FAT/CD36 and FABPpm expression.
At the end of the experiments cardiac myocytes were washed
twice with PBS buffer and prepared for Western blotting as
previously described [20].
To ascertain the signaling pathways that are involved
in the AICAR-induced regulation of the LCFA transporter
proteins, cardiac myocytes were pretreated for 1 h with
selected inhibitors, followed by treatment with AICAR
(2 mM, 120 min). The inhibitors used were as follows: AMP
kinase competitive inhibitor: ARA (2.5 mM) (adenine 9-β-D-
arabino-furanoside) [42, 43]; PKC-ps: myristoylated Protein
Kinase C ζ /λ pseudosubstrate inhibitor, (10 μM), which has
been used as a cell-permeable specific inhibitor of PKC ζ /λ
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kinases [44]; UO 126 has been used at a concentration of
10 μM as a highly selective inhibitor of the MAP kinases,
MEK1 and MEK2 [45]; and finally, LY294002 was shown
to act as highly selective inhibitor of phosphatidylinositol 3
kinase (PI3K), and at a concentration of 50 μM does not in-
hibit lipid and protein kinases such as PI 4 kinase, PKC, MAP
kinase or c-Src [46].
Effects of AICAR on LCFA uptake and oxidation
by cardiac myocytes
To examine the effects of AICAR (2 mM) exposure on ini-
tial rates of palmitate uptake by cardiac myocytes we used
the procedure of Luiken et al [12, 18, 22]. For these pur-
poses 0.6 ml of a [1-14C]palmitate-BSA complex was added
to 1.8 ml of cardiac myocyte suspension at the end of the incu-
bation period, (final palmitate concentration 100 μM, palmi-
tate/BSA ratio of 0.3). Palmitate uptake was stopped after
3 min by adding an ice-cold stop solution (KHB buffer sup-
plemented with 0.1% BSA (w/v), 1 mM CaCl2 and 0.2 mM
phloretin). Subsequently, cells were washed twice (60×g for
2 min) with the stop solution. The final pellet was assayed for
radioactivity.
Rates of palmitate oxidation were determined under the
same experimental conditions, using procedures that we have
described previously [47, 48]. Briefly, 30 min before the
end of the incubation period, 0.6 ml of a [1-14C]palmitate-
BSA complex was added to 1.8 ml of cardiac myocytes
suspension, (final palmitate concentration 100 μM, palmi-
tate/BSA ratio of 0.3). During the final 30 min of incubation
14CO2 was trapped in benzothium hydroxide and assayed for
radioactivity.
Heart perfusion, giant vesicles preparation and LCFA
transport
Isolated hearts were perfused with or without AICAR (2 mM,
120 min), in the Langendorff mode, using continuously
gassed (95%O2–5%CO2) medium A as we [18, 20, 26, 47]
have previously reported. After 2 h, the ventricles were re-
moved and were frozen in liquid nitrogen and stored at
−80 ◦C until analyzed for FAT/CD36 and FABPpm using
Western blotting.
Hearts perfused with and without AICAR (2 mM, 120 min)
were also used to examine LCFA transport into giant vesicles.
After 2 h of perfusion the ventricles were removed and placed
in KCl/MOPS buffer (140 mM KCl, 10 mM MOPS, pH 7.4).
To prepare giant sarcolemmal vesicles we used procedures
reported previously [20, 49]. Briefly, perfused ventricles were
scored into strips with a scalpel and incubated for 1 h at
34 ◦C in KCl/MOPS buffer supplemented with 0.142 mg/mL
PMSF, 1.0 mg/mL aprotinin, and 150 U/mL type II collage-
nase. The incubation medium was collected and the ventri-
cles were washed with 10 mM EDTA in KCl/MOPS until
7 mL had been collected. Percoll was added to the collected
medium in a volume ratio of 7:30. This mixture was slowly
pipetted under a density gradient of 3 ml 4% w/v Nycodenz,
on top of which 1 mL KCl/MOPS was layered. The sam-
ples were centrifuged in a swinging bucket rotor (Beckman)
at 60 × g for 45 min at room temperature. After centrifuga-
tion, the vesicles were collected from the interface between
the Nycodenz and KCl/MOPS solutions. The vesicles were
pelleted at 12000 × g for 5 min at room temperature. The su-
pernatant was aspirated and the vesicles slightly diluted with
KCl/MOPS supplemented with PMSF. Vesicles were used
immediately for LCFA transport. Some vesicles were also
stored at −80 ◦C until analyzed for plasmalemmal fatty acid
transporters.
LCFA transport was performed as we have previously
reported [22, 49]. Briefly, a reaction medium (unlabelled
palmitate, radiolabelled [3H]-palmitate (0.3 μCi,) and [14C]-
mannitol (0.06 μCi) dissolved in 0.1% BSA-KCl/MOPS so-
lution) was added to the vesicles (40–80 μg protein) and incu-
bated for 15 s at room temperature. A stop solution (2.5 mM
HgCl in 0.1%BSA-KCl/MOPS) was added and the sample
immediately centrifuged (12000×g, 2 min). The supernatant
fraction was aspirated and the bottom of the tube containing
the pellet was cut off and placed in a scintillation vial. Stan-
dard liquid scintillation techniques were used to measure the
radioactivity.
Western blotting
At the end of the experiments total FAT/CD36 and FABPpm
protein expression was determined in cardiac myocytes and
perfused intact hearts. For these purposes cardiac myocytes
were washed twice with PBS buffer and homogenized and
re-suspended in Buffer 2 (Tris-base 10 mM, EDTA 1 mM,
pH 7.4) and frozen in liquid nitrogen. From perfused hearts,
homogenates yielding crude membranes were prepared as de-
scribed previously [20, 26]. FAT/CD36 and FABPpm were
also determined in PM and LDM fractions from subfrac-
tionated cardiac myocytes, as well as in plasma membranes
from giant vesicles obtained from perfused hearts. Routine
Western blotting procedures were used to detect proteins as
described previously [18, 20, 22]. Protein content was deter-
mined with bicinchonic acid method with BSA serving as
a protein standard. Briefly, all samples were separated using
10% SDS-polyacrylamide gel electrophoresis and polyclonal
antiserum was applied. Signals obtained by Western blot-
ting were quantified by densitometry using chemilumines-




Total RNA was isolated from cardiac myocytes using TriPure
Isolation Reagent (Roche, Indianapolis, IN). 3–5 μg of the
total RNA was loaded on a formaldehyde gel for each sam-
ple, electrophoresed at 100 V for 2.5 h and transferred to
positively charged nylon membranes (Roche, Indianapolis,
IN). Equal loading of RNA and even transfers were con-
firmed by Blot Stain Blue (Sigma-Aldrich, Oakville, ON).
FAT/CD36 and FABPpm DIG labelled probes were gener-
ated using a digoxigenin (DIG) RNA labelling mix (Roche,
Indianapolis, IN). Membranes were prehybridized for 30–
60 min at 68 ◦C in a standard hybridization buffer (con-
taining 25% (FAT/CD36) or 50% (FABPpm) deionized for-
mamide, 5 × SSC, 0.1% N-lauroyl-sarcosine, 0.02% SDS,
and 2× Blocking Solution (Roche, Indianapolis, IN). Mem-
branes were hybridized overnight at 68 ◦C in 1 μ g of DIG
labelled probe per 10 ml of hybridization buffer. Membranes
were washed, blocked in 1X Blocking Solution for 30 min
and incubated with anti-Digoxigenin-AP antibody (1:10 000)
for 30 min. Signal detection was performed using CDP-Star
chemiluminescent substrate (Roche, Indianapolis, IN). Blots
were visualized and quantified using the ChemiGenius2 Bio
Imaging System (Perkin Elmer, Boston).
Statistics
All presented data are expressed as mean ± S.E.M. Depend-
ing on the experiment, statistical differences were tested with
either a t-test or with an analysis of variance and Fisher’s least
squares differences post-hoc test. Statistical significance was
set at P ≤ 0.05.
Results
Dose and time dependent effects of AICAR on cardiac
myocyte FABPpm and FAT/CD36
We exposed freshly isolated cardiac myocytes to AICAR
(2 mM) for up to 3 h. At selected time points the cells were
harvested. In control experiments (no AICAR), FAT/CD36
and FABPpm proteins were not altered during the incu-
bation period (Fig. 1A). In contrast, in the presence of
AICAR, the expression of both FAT/CD36 and FABPpm was
increased during the 3 h incubation period. No changes were
observed within first 30 min, but after 60 min (+12%) and
90 min (+27%) FABPpm protein was increased (P < 0.05)
and FABPpm upregulation remained quite stable from 60–
150 min (Fig. 1A, P < 0.05). FAT/CD36 was also increased
after 60 (+38%) and 90 min (+44%) (Fig. 1A, P < 0.05).
This protein also remained stably upregulated.
With increasing AICAR concentrations we observed a
dose-dependent increase in the expression of both FAT/CD36
and FABPpm proteins. Both FAT/CD36 and FABPpm pro-
teins increased progressively as the concentration of AICAR
was increased (0–8 mM, Fig. 1B, P < 0.05) attaining a
plateau at the concentration of 1–5 mM for FABPpm and
2–8 mM for FAT/CD36 (Fig. 1B). During this time, AICAR
(2 mM, 120 min) exposure increased both FABPpm mRNA
(+238%) and FAT/CD36 mRNA (+159%) (P < 0.05,
Fig. 2)
Effects of AICAR on LCFA transporters FABPpm and
FAT/CD36 in intact hearts
To determine whether AICAR-induced upregulation of both
LCFA transporters in cardiac myocytes also occurs in intact
hearts, we examined the effect of AICAR in Langendorff
perfused hearts. Perfusion of the hearts for 2 h with AICAR
(2 mM) increased both FABPpm (+23%) and FAT/CD36
(+36%) protein expression (P < 0.05, Fig. 3A). Similar
AICAR-induced increments were also observed for FABPpm
(+27%) and FAT/CD36 (+44%) in cardiac myocytes (P <
0.05, Fig. 3B).
Effects of AICAR on LCFA transporters and transport
into giant vesicles
To examine whether the AICAR-induced effects on fatty
acids transporters can alter LCFA transport into the heart,
we determined the rate of LCFA transport into giant vesi-
cles derived from the 2 h AICAR-perfused hearts. In the
AICAR-perfused hearts the rates of palmitate transport into
giant vesicles were significantly elevated (2.5 fold, Fig. 4A,
P < 0.05). This was associated with concomitant increases
in both FABPpm and FAT/CD36 at the plasma membranes
after 2 h exposure to AICAR (+42% and +49%, respectively,
Fig. 4B, P < 0.05).
Signaling pathways involved in AICAR-induced FABPpm
and FAT/CD36 overexpression
We examined possible signaling pathways involved in the
AICAR-induced FAT/CD36 and FABPpm upregulation in
cardiac myocyte. As has been shown previously [18, 50],
exposure of cardiac myocytes to AICAR (2 mM, 15 min.)
increased the ACC and AMPK phosphorylation (Fig. 5A
and B, 4.5 fold and 1.9 fold, respectively). As reported else-
where [18, 50], AICAR also induced the phosphorylation of
MEK1/2 (4.9 fold data not shown), ERK1/2 (1.7 fold, data
not shown) and PKC ζ /λ (1.7 fold, data not shown). AICAR
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Fig. 1. Time dependent (0–180 min) effects of AICAR (2 mM) (A) and dose (0–8 mM, 2 h) response effects of AICAR (B) on FAT/CD36 and FABPpm protein
expression in cardiac myocytes. (mean ± sem). Panel A: For the time course studies, cardiac myocytes were prepared from rat hearts and incubated for varying
periods of time at 37 ◦C in the absence and presence of AICAR. Data are based on 4 independent determinations at each time point. ∗ P < 0.05, FAT/CD36:
AICAR vs control at each time point. ∗∗ P < 0.05, FABPpm: AICAR vs control at each time point. Panel B: For the dose response studies, cardiac myocytes
were prepared from rat hearts and incubated for 2 h at 37 ◦C in the absence and presence of AICAR. Data are based on 6–11 independent determinations at
each concentration. Note the log scale. Reference points for FAT/CD36 and FABPpm are 100% in the absence of AICAR. ∗ P < 0.05, FAT/CD36: AICAR vs
no AICAR. ∗∗ P < 0.05, FABPpm: AICAR vs no AICAR.
did not induce the phosphorylation of Akt (ser 473, data not
shown), as previously observed [51].
To establish the signalling pathways that could potentially
be involved in regulating FABPpm and FAT/CD36 expres-
sion, selected specific inhibitors were used to block phos-
phorylation of Akt, AMPK, MEK1/2 and PKC ζ /λ. These
studies showed that it was possible to block (a) AICAR-
induced phosphorylation of AMPK and ACC by adenine 9-
β-D-arbino-furanoside (ARA) (Fig. 5A and B), and (b) to
block the AICAR-induced phosphorylation of PKC ζ /λ ki-
nases by myristoylated protein kinase C ζ /λ pseudosubstrate
(PKC-ps) and MEK1/2 by UO 126 (data not shown). How-
ever, blocking the phosphorylation of MEK1/2 and PKC ζ /λ
did not affect the AICAR-induced expression of FABPpm and
FAT/CD36 (data not shown). In contrast, the AICAR-induced
increase in the expression of both FABPpm and FAT/CD36
was completely inhibited (Fig. 6A and B), when the AMPK
signalling pathway was blocked by ARA. Correspondingly,
at the functional level, 2 h AICAR exposure stimulated the
uptake and oxidation of palmitate by cardiac myocytes (Fig.
6C and D). However, when the AICAR-induced phosphory-
lation of AMPK was blocked by ARA, palmitate uptake and
oxidation into cardiac myocytes were also blocked (Fig. 6C
and D).
Discussion
We have previously shown that AICAR induces the translo-
cation of FAT/CD36 and FABPpm, but not FATP1 [26]. In
those studies we were careful to establish that protein ex-
pression was not altered, by maintaining only a short dura-
tion exposure to AICAR (30 min) [26]. In the present stud-
ies there was a very different focus. Specifically, we exam-
ined whether AICAR induced the expression of FAT/CD36
and FABPpm, the signalling pathway involved, and the ef-
fects of upregulating FAT/CD36 and FABPpm on LCFA
transport.
Our present studies have provided evidence for a novel
role for AICAR-induced AMPK activation in the regulation
of protein-mediated LCFA entry into the heart. We found
(a) that AICAR very rapidly induced (i) the overexpression
of both FAT/CD36 and FABPpm at the mRNA level and
(ii) upregulated both FABPpm and FAT/CD36 proteins in a
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Fig. 2. Effects of AICAR on FAT/CD36 mRNA (A) and FABPpm mRNA (B) in cardiac myocytes. Cardiac myocytes were prepared from rat hearts and
incubated for 2 h at 37 ◦C in the absence and presence of AICAR (2 mM). Data are based on 3–4 independent determinations at each time point (mean ± sem).
∗ P < 0.05 AICAR-treated cardiac myocytes at 120 min vs control cardiac myocytes at t = 0 and 120 min.
Fig. 3. Comparison of the effects of AICAR on FAT/CD36 and FABPpm protein expression in Langendorff perfused hearts (A) and in cardiac myocytes (B).
Hearts were perfused for 2 hours at 37 ◦C in Langendorff mode in the absence and presence of AICAR (2 mM). Cardiac myocytes were prepared from rat hearts
and incubated for 2 h at 37 ◦C in the absence and presence of AICAR (2 mM). Data are based on 4 independent determinations for perfused hearts and cardiac
myocytes (mean ± sem). ∗ P < 0.05, AICAR vs control.
time- and dose-dependent manner, (b) the AICAR-induced
expression of both LCFA transport proteins was quantita-
tively similar in cardiac myocytes and in the intact, Langen-
dorff perfused hearts, (c) AMPK activation not only increased
LCFA transporter expression, but AMPK activation also tar-
geted these transporters to the plasma membrane, (d) this
increase in plasmalemmal FA transporters was associated
with an increased the rate of LCFA transport into the heart,
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Fig. 4. Effects of AICAR on (A) the rates of palmitate transport into giant vesicles and (B) plasmalemmal FAT/CD36 and FABPpm proteins. Hearts were
perfused in Langendorff mode at 37 ◦C for 2 h in the absence and/or presence of AICAR (2 mM). Thereafter, the rates of palmitate transport into giant vesicles
were determined and Western blotting was performed on plasma membranes derived from the giant vesicles. Data are based on 3–4 independent determinations
for each treatment (mean ± sem). ∗ P < 0.05, AICAR vs control.
Fig. 5. Effects of AICAR and AICAR + selected inhibitors on the phosphorylation of AMPK and ACC proteins. Data are based on 3 independent determinations
for each treatment (mean ± sem). ∗ P < 0.05, treatment vs control. Cardiac myocytes, prepared from rat hearts, were preincubated for 1 h at 37 ◦C, in the
absence and/or presence of inhibitors, followed by incubation with AICAR (2 mM) for 15 min. The inhibitors used were as follows: ARA (10 μM, adenine
9-β-D-arabino-furanoside), PKC-ps (10 μM, myristoylated Protein Kinase C ζ /λ pseudosubstrate inhibitor); UO 126 (10 μM inhibitor of the MAP kinases);
LY294002 (50 μM inhibitor of phosphatidylinositol 3 kinase).
and (e) concomitantly there was a concurrent increase in
LCFA oxidation, possibly as a result of the increased rate
of LCFA transport. Importantly, (f) these AICAR-induced
effects on protein expression, and fatty acid uptake and oxi-
dation were prevented when the AMP-kinase signaling path-
way was blocked.
The AICAR induction of LCFA transporter protein ex-
pression was very rapid, being already evident after 60
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Fig. 6. Effects of AICAR and AICAR+ARA (10 μM, adenine 9-β-D-
arabino-furanoside) on the expression of FABPpm (A) and FAT/CD36 (B),
as well as on the rate of palmitate uptake (C) and oxidation (D) by cardiac
myocytes. (mean ± sem). ∗ P < 0.05, treatment vs control. For these stud-
ies cardiac myocytes, were preincubated for 1 hour at 37 ◦C in the absence
and/or presence of the inhibitor, followed by incubation with AICAR (2 mM)
for 2 hours. Palmitate uptake (3 min) rate was determined at the end of the
incubation period while palmitate oxidation was determined during the final
30 min of incubation.
(FAT/CD36) and 90 min (FABPpm). Their up-regulation re-
mained stable from 90 to 150 min for both LCFA transport
proteins. This rapid increase in protein expression paral-
lels another study, in which, within 30–200 min., a 1.5–
6.0 fold increase in UCP3 protein was observed in skele-
tal muscles incubated with AICAR [33]. Furthermore, we
[20] have recently shown that insulin rapidly stimulated, via
the PI3-kinase/Akt signaling pathway, the overexpression of
cardiac myocyte FAT/CD36 protein within 2 h, in a time
and dose-dependent manner. But in marked contrast to the
present study, insulin did not alter the expression of FABPpm
[20]. This indicates that, in the same tissue, there are LCFA
transporter-specific responses to different stimuli such as in-
sulin and AICAR, involving different signaling pathways (i.e.
PI3 kinase and AMPK, respectively). We also observed that
AICAR induced a strikingly similar effect on the overexpres-
sion of both fatty acid transporters in cardiac myocytes and
in the perfused heart, suggesting that our observations are
relevant in vivo.
Recent studies have provided evidence that AICAR can
activate a number of different signaling pathways [52, 53],
although little is known as to which one of these is in-
volved in the AICAR-induced protein synthesis in cardiac
myocytes. AICAR stimulation of the AMPK cascade pro-
motes activation of pathways to promote ATP generation
and inhibits anabolic pathways to limit ATP consumption.
Thus, in general, AMPK activation inhibits glycogen, choles-
terol, fatty acids and protein synthesis [54, 55]. Nevertheless,
in present study we demonstrated that in cardiac myocytes
AMPK activation very rapidly stimulated protein synthesis of
the fatty acids transporters, FAT/CD36 and FABPpm. Inhibi-
tion with selective blockers of several AICAR-stimulated sig-
nalling pathways demonstrated conclusively that FAT/CD36
and FABPpm expression occurs via the AMPK signalling
pathway.
As with any inhibitor, ARA may well have nonspe-
cific effects. However, the ARA concentrations used in
the present study (2.5 mM) are similar to those used by
others [42, 43, 56]. In these recent studies this precursor
of ara-ATP, a competitive inhibitor of AMPK, inhibited
AICAR-stimulated glucose transport in epitrochlearis mus-
cle (2.5 mM ARA, [43]) and papillary muscle (2 μM–10 mM
ARA, [56]), and prevented AMPK-mediated GLUT4 up-
regulation in L6 myotubes (1 mM ARA, [42]). ARA ap-
pears to inhibit AMPKα2 activity but not AMPKα1 activ-
ity [43]. Thus, in the present study and others [42, 43, 56]
ARA has proven to be a useful inhibitor with which to deter-
mine whether AMPK activation regulates selected metabolic
processes.
In the present study, we observed that AICAR not only
increases FAT/CD36 and FABPpm expressions, but it also
appears to targets both of these transporters to the plasma
membrane as shown in the giant vesicles. We are aware
that FABPpm is identical to the mitochondrial aspartate
aminotransferase [57, 58] and we have shown recently that
FAT/CD36 is also present in mitochondria [59]. However,
our subcellular PM and LDM fractions are not contaminated
with mitochondria (data not shown and [20]).
The dual effect of long-term AICAR exposure on fatty
acid transporter expression and their increased plasmalem-
mal content in the heart is similar to that observed for GLUT4
in fast-twitch muscle exposed to AICAR for 5 days; namely,
there was an increase in both GLUT4 protein expression and
an increase in plasmalemmal GLUT4 [60]. Presumably, the
increased plasmalemmal FABPpm and FAT/CD36 reflected
the increased protein expression, since the AICAR-induced
increases in plasmalemmal protein and their expression were
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very similar (FABPpm protein expression +27% and plasma
membrane FABPpm +38%; FAT/CD36 protein expression +
44% and plasma membrane FAT/CD36 +44%). Such similar
changes were also observed with long-term (5 day) AICAR
treatment on GLUT4 expression (+63%) and plasmalem-
mal GLUT4 content (+68%) in skeletal muscle [60]. We and
Buhl et al. [60] assume that this dual effect on the expression
and subcellular localization of glucose and fatty acid trans-
porters is attributable to the well known activation of AMPK
by AICAR.
The present studies have also shown the metabolic con-
sequences of AICAR induced changes in the LCFA trans-
porters. This is the first study to show that AICAR-induced
an increase in myocardial LCFA transport into giant vesicles,
the most suitable system for measuring fatty acid transport
[49, 61]. The AICAR-stimulated increase in LCFA trans-
port correlated positively with the increase in plasmalemmal
FAT/CD36 and FABPpm. It has been reported in several stud-
ies that the changes in subcellular localization of fatty acid
transporters show a strong positive relationship with fatty
acid transport [13, 17, 18, 22]. Our present observations un-
derscore the fact that the subcellular redistribution of LCFA
transporters is an important factor that determines cardiac
myocytes capacity for fatty acid transport. It is tempting to
speculate that this increased rate of fatty acid transport is
necessary to ensure sufficient fatty acid provision for mito-
chondrial oxidation when AMPK is activated. Others have
also speculated that it is the increased fatty acid delivery into
the heart that provides the additional substrate for oxidation
[3, 11, 62].
In summary, this study has shown that AMPK activation
by AICAR very rapidly (1–2 h) stimulates the protein expres-
sion of both fatty acid transporters, FAT/CD36 and FABPpm,
in cardiac myocytes in (a) time- and (b) dose-dependent man-
ner, by (c) transcriptional mechanisms. Importantly, (d) the
expression of FAT/CD36 and FABPpm is regulated by the
AMPK signaling pathway. In addition, (e) AICAR-induced
expression of LCFA transporters was similar in cardiac my-
ocytes and the perfused heart. Finally, (f) there was a positive
correlation between the plasmalemmal content of both fatty
acids transporters and the rates of LCFA transport into gi-
ant vesicles. Thus, prolonged activation of AMPK is a key
mechanism regulating the expression fatty acid transporters.
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